Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3‐Way Crossover Trial

Abstract Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox–Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti‐seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti‐epileptic and sedative properties of CBD. A randomized, double‐blind, placebo‐controlled, 3‐way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD,